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in the literature. These differences result not only 
from the varied prevalence of the 2 conditions but 
also from their underlying pathophysiology and 
comorbidities. Type 1 diabetes is characterized by 
absolute insulin deficiency and usually occurs in 
persons without concomitant disorders at diag‑
nosis.1,7,8 On the other hand, type 2 diabetes typ‑
ically coexists with insulin resistance and numer‑
ous cardiovascular risk factors.8
INTRODUCTION Type 1 diabetes is a predomi‑
nant form of diabetes in children, adolescents, 
and young adults.1 Compared with type 2 diabe‑
tes, the occurrence of type 1 diabetes has been 
growing less dynamically and fewer studies have 
investigated its complications.1-6
Although type 1 and type 2 diabetes are 2 dis‑
tinct disease entities, the differences between them 
do not seem to have been adequately addressed 
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ABSTRACT
INTRODUCTION It is widely believed that patients with diabetes are at increased risk of severe and 
premature coronary artery disease (CAD) when compared with nondiabetic individuals.
OBJECTIVES The aim of the study was to evaluate the prevalence, 7 -year incidence, predictors, and 
outcomes of obstructive and nonobstructive CAD in patients with long -lasting type 1 diabetes.
PATIENTS AND METHODS We enrolled 2330 patients at a median age of 50 years and a median diabetes 
duration of 32 years. All participants underwent diagnostic workup for CAD with an exercise treadmill 
test (ETT), single -photon emission computed tomography (SPECT), or both. Coronary angiography was 
performed in patients with abnormal ETT/SPECT results and repeated during the study if clinically indicated.
RESULTS The prevalence of obstructive and nonobstructive CAD was 6.9% and 42%, respectively, while 
the 7 -year incidence, 1.9% and 7.4%, respectively. Of the 160 revascularized patients, 38% underwent 
complete revascularization. Acute coronary syndromes were reported in 3.6% of patients (54% with 
nonobstructive CAD). Cardiac deaths were reported in 1.07% of the population, and only in patients with 
obstructive CAD. Age, diabetes duration, hypertension, and renal failure were predictors of obstructive CAD, 
while type 1 diabetes duration, glycated hemoglobin A1c levels, frequent severe hypoglycemia, hyperten-
sion, triglyceride levels, renal failure, and cardiac autonomic neuropathy predicted nonobstructive CAD.
CONCLUSIONS Nonobstructive CAD was the most frequent coronary complication in patients with type 
1 diabetes. Both obstructive and nonobstructive CAD showed a similar incidence of nonfatal outcomes 
and selected predictors. Positive ETT/SPECT results were related to glycemic control only in patients 
with nonobstructive CAD.
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exercise intolerance (shortness of breath, fatigue, 
or nausea already at a workload of 5 metabolic 
equivalents), and an insufficient increase in ar‑
terial blood pressure of less than 30 mm Hg or 
a decrease below the resting blood pressure value. 
Some patients underwent ETT as the first pro‑
cedure, followed by SPECT, according to the cri‑
teria described above. The procedures were re‑
peated at 7 years of follow ‑up and, additionally, 
when necessary during the study.
The criteria for positive ETT results included 
chest pain, shortness of breath increasing on ex‑
ercise and resolving at rest, and one of the follow‑
ing: 1) horizontal or downsloping ST ‑segment de‑
pression ≥1 mm in 2 or more electrocardiographic 
leads 60 to 80 ms from the J point in 3 consecu‑
tive beats in patients without preexcitation, atri‑
al fibrillation or flutter, pacemaker, resting LBBB, 
resting repolarization abnormalities; or 2) exer‑
cise‑related ventricular tachycardia or LBBB in 
patients with typical angina symptoms.
The criteria for positive SPECT results includ‑
ed reversible perfusion defects in 2 or more of 
the 17 segments, or reversible perfusion defects 
in over 10% of the myocardial area, or multiple 
ischemic perfusion defects in more than 1 coro‑
nary artery territory. Participants with inabil‑
ity or contraindications to exercise underwent 
SPECT with vasodilator or inotropic agents. 
During follow ‑up, ETT/SPECT was repeated 
when necessary.
Subsequently, quantitative coronary angi‑
ography was used for segmental analysis of 
the coronary arteries in patients with posi‑
tive results of ETT/SPECT at baseline and was 
repeated during follow ‑up and at the end of 
the study if clinically indicated (acute coronary 
syndrome [ACS] during follow ‑up, abnormal 
ETT/SPECT results).
Based on coronary angiography findings and 
positive ETT/SPECT results, patients were di‑
vided into 2 major subgroups: 1) patients with 
obstructive CAD, defined as coronary stenosis 
of 70% or greater in the epicardial coronary ar‑
tery, or of 50% or greater in the left main coro‑
nary artery, or when the fractional flow reserve 
was equal to or less than 0.80 in patients with 
borderline coronary lesions on angiography; and 
2) patients with nonobstructive CAD: type A, de‑
fined as normal coronary anatomy (<20% ste‑
nosis) in all coronary arteries, and type B, de‑
fined as any stenosis of 20% or greater but less 
than 70%, narrowing in any epicardial artery, or 
stenosis of 20% or greater but less than 50% in 
the left main coronary artery.
Premature obstructive CAD was defined as 
a diagnosis of obstructive CAD in patients under 
45 years of age. Complete revascularization was 
defined as treatment with percutaneous coro‑
nary intervention (PCI) or coronary artery bypass 
grafting (CABG) of any lesion with stenosis of 
70% or greater in the vessels with a diameter of 
2 mm or higher, or stenosis of 50% or greater in 
the left main coronary artery supplying the viable 
It is widely believed that patients with diabe‑
tes are at increased risk of severe and premature 
obstructive coronary artery disease (CAD), com‑
pared with nondiabetic individuals.1,7,8 None‑
theless, the real prevalence of vascular compli‑
cations, including obstructive and nonobstruc‑
tive CAD, in patients with type 1 diabetes re‑
mains unknown.
The aim of the present study was to evalu‑
ate the prevalence, 7 ‑year incidence, predictors, 
and outcomes of obstructive and nonobstructive 
CAD in patients with long ‑lasting type 1 diabetes.
PATIENTS AND METHODS Patients Between 
the years 2001 and 2003, we enrolled 2350 pa‑
tients with a clinical diagnosis of type 1 diabe‑
tes, defined as previously described,9 and a dura‑
tion of diabetes longer than 15 years. The study 
population was randomly selected (by the com‑
puter random number generator) from patients 
treated in diabetology clinics in 3 southern Pol‑
ish voivodships (Małopolska, Podkarpackie, and 
Świętokrzyskie).
Patients underwent diagnostic procedures for 
CAD (see below), as well as the assessment of car‑
diovascular risk factors and chronic diabetic com‑
plications at baseline and at 7 years of follow ‑up. 
During follow ‑up, we contacted participants as 
well as their diabetologists and family doctors 
at the place of residence, by phone or email ev‑
ery 6 months (or when necessary). Patients could 
contact us at any time in case their health status 
deteriorated. If necessary, patients were invited 
to our department for a comprehensive differ‑
ential diagnosis and treatment during follow‑
‑up. At baseline, 20 patients refused to give in‑
formed consent to participate in the study, re‑
sulting in a study sample of 2330 participants. 
A total of 2303 patients completed the study. 
The distribution of patients at baseline and dur‑
ing follow ‑up is presented in FIGURE 1.
The study protocol complied with the Declara‑
tion of Helsinki and was approved by the Ethics 
Committee of Jagiellonian University Medical 
College (KBET/335/B/2001, to EK). Each study 
participant provided written informed consent 
before enrollment.
Diagnostic procedures All participants under‑
went physical examination, medical history tak‑
ing, assessment of chronic diabetes complica‑
tions, echocardiography, exercise treadmill test 
(ETT) or single ‑photon emission computed to‑
mography (SPECT) with technetium 99m (99mTc), 
as well as laboratory tests.
SPECT was performed when ETT was contra‑
indicated or not suitable to exclude myocardial 
ischemia, namely, in cases of silent myocardial 
ischemia on ETT, preexcitation syndrome on elec‑
trocardiography, pacemaker, atrial fibrillation or 
flutter, resting or asymptomatic exercise ‑related 
left bundle branch block (LBBB), exercise‑related 
ventricular tachycardia in patients without typi‑
cal angina, resting repolarization abnormalities, 
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Cardiac autonomic neuropathy (CAN) was de‑
fined as the impairment of autonomic nerve fi‑
bers that innervate the heart and blood vessels, 
resulting in abnormalities in heart rate control 
and vascular dynamics after exclusion of other 
causes of dysautonomia.10,11 In our study, CAN 
was diagnosed by cardiovascular autonomic reflex 
tests based on the assessment of heart rate re‑
sponse to deep breathing, standing, the Valsal‑
va maneuver (not advisable in patients with ad‑
vanced proliferative retinopathy); blood pressure 
myocardium. Coronary lesions not suitable for 
revascularization were defined as chronic total 
occlusions in single ‑vessel disease not involving 
the left anterior descending artery, side small 
branch stenoses or distal coronary lesions, and 
diffuse atherosclerotic lesions from the proximal 
to distal beds, leading to a thread ‑like appearance 
with small (<2 mm) distal runoff. Hypertension 
was defined as a blood pressure of 140/90 mm Hg 
or higher on at least 2 separate measurements, 
or the use of antihypertensive drugs.
TABLE 1 Patient characteristics and treatment at baseline and at 7 -year follow -up
Variables Baseline 
(n = 2330)
At 7 years  
(n = 2303)
P value
Age, y 50 (40–59) 57 (47–66) –
Female sex, n (%) 1126 (48.3) 1126 (48.9) –
Diabetes duration, y 32 (22–44) 39 (29–51) –
BMI, kg/m2 23.4 (21.0–24.6) 23.7 (22.0–26.5) <0.0001
SBP, mm Hg 135.0 (127.0–140.0) 130.0 (120.0–135.0) <0.0001
DBP, mm Hg 87.0 (80.0–89.0) 78.0 (70.0–83.0) <0.0001
Medical history
Cigarette smoking, n (%) 84 (3.6) 60 (2.6) <0.0001
Heart failure, n (%) 175 (7.5) 183 (8.0) 0.01
Hypertension, n (%) 1749 (75.1) 1767 (76.7) 0.001
Impaired renal functiona, n (%) 559 (21) 628 (27.2) <0.0001
End -stage renal disease, n (%) 21 (0.9) 27 (1.1) 0.007
Albuminuria, n (%) 422 (18.1) 518 (22.5) <0.0001
Peripheral neuropathy, n (%) 1118 (48) 1290 (56) <0.00 001
Peripheral atherosclerosis, n (%) 198 (8.5) 212 (9.2) <0.0001
Cardiac autonomic neuropathy, n (%) 508 (21.8) 532 (23.1) <0.0001
Frequent severe hypoglycemia, n (%) 256 (11.0) 268 (11.6) <0.0001
Any retinopathy, n (%) 1701 (73) 1819 (78.9) 0.004
Proliferative retinopathy, n (%) 839 (36) 869 (37.7) 0.03
Laboratory investigations
HbA1c, % 7.6 (7.0–8.1) 7.3 (6.8–8.2) <0.0001
eGFR, ml/min/1.73 m² 90.0 (80.0–99.0) 85.0 (76.0–93.0) <0.0001
LDL -C, mmol/l 3.0 (2.4–3.4) 2.3 (1.7–2.7) <0.0001
HDL -C, mmol/l 1.1 (0.8–1.4) 1.2 (1.0–1.5) <0.0001
Triglycerides, mmol/l 1.3 (1.0–1.5) 0.9 (0.7–1.2) <0.0001
Pharmacological treatment
Statins, n (%) 1084 (46.5) 1105 (48.0) <0.0001
ACEIs, n (%) 1407 (60.4) 1427 (62.0) <0.0001
ARBs, n (%) 334 (14.3) 350 (15.2) <0.0001
β -Blockers, n (%) 470 (20.2) 492 (21.4) <0.0001
CCBs, n (%) 1509 (64.8) 1639 (71.2) <0.0001
Diuretics, n (%) 321 (13.8) 405 (17.6) <0.0001
Fibrates, n (%) 31 (1.3) 51 (2.2) <0.0001
Antiplatelet agents, n (%) 1958 (84.0) 942 (84.3) 0.0009
Data are shown as median (interquartile range) unless otherwise indicated.
a Defined as eGFR <60 ml/min/1.73 m2
Abbreviations: ACEI, angiotensin -converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass 
index; CCB, channel calcium blocker; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, 
glycated hemoglobin A1c; HDL -C, high -density lipoprotein cholesterol; LDL -C, low -density lipoprotein cholesterol; SBP, 
systolic blood pressure
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the Bowker test for categorical variables. All sta‑
tistical tests were 2 ‑sided with an α value of 0.05. 
A multiple regression analysis was used to assess 
the predictors of the prevalence of both obstructive 
and nonobstructive CAD. A logistic regression anal‑
ysis was used to investigate the odds for the occur‑
rence of new cases of obstructive and nonobstruc‑
tive CAD during follow ‑up. The prevalence was de‑
fined as the total number of obstructive or nonob‑
structive CAD cases at baseline and at 7 years, cal‑
culated per 1000 participants, while the incidence 
was defined as the number of new obstructive or 
nonobstructive CAD cases in the study population 
per year over the 7 ‑year follow ‑up, calculated per 
1000 participants. The statistical analysis was per‑
formed using the JMP 13.1.0 software (SAS Insti‑
tute Inc., Poland).
RESULTS The  final study sample included 
2330 patients with type 1 diabetes. The charac‑
teristics of the study population, as well as data on 
treatment and concomitant disorders, are shown 
in TABLE 1. At baseline, the ETT and SPECT were 
performed in 31% and 69% of the study group, 
respectively. Of the study group, 1130 patients 
(48.4%) showed positive ETT/SPECT results 
and underwent coronary angiography at base‑
line (FIGURE 1). Angiography was repeated dur‑
ing follow ‑up and at the end of the study if clini‑
cally indicated (ACS during follow ‑up, abnormal 
ETT/SPECT results).
Study outcomes, predictors, and follow -up The base‑
line prevalence and 7 ‑year incidence were 6.9% 
and 1.9%, respectively, for obstructive CAD, and 
41.6% and 7.4%, respectively, for nonobstruc‑
tive CAD (TABLE 2 and FIGURE 1). Among patients 
with nonobstructive CAD, type A was observed 
in 72.5% and type B in 27.5.% (FIGURE 1).
The multivariate analysis did not show signifi‑
cant differences between sexes in the occurrence 
of the predictors. The results of univariate and 
multivariate analyses in the whole study popu‑
lation are presented in TABLES 3 and 4. Diabetes 
duration, hypertension, and renal impairment 
were predictors of both obstructive and nonob‑
structive CAD, whereas HbA1c levels, CAN, fre‑
quent severe hypoglycemia, and triglyceride lev‑
els were predictors only of nonobstructive CAD. 
On the other hand, aging was a predictor only of 
obstructive CAD (TABLE 3).
At diagnosis, patients with obstructive CAD 
were older than those with nonobstructive CAD: 
median age, 61 years (range, 56–67 years) vs 
51 years (range, 46–62 years) (P = 0.001). Ob‑
structive CAD was more prevalent in men than 
in women: 108 (67.5%) vs 52 (32.5%), P <0.0001, 
and women were older than men at diagnosis of 
obstructive CAD: median age, 64 years (range, 
59–70 years) vs 55 years (range, 52–67 years), P = 
0.003. Premature obstructive CAD was revealed 
in only 0.09% of the patients. About 60% of pa‑
tients with nonobstructive CAD had albumin‑
uria, while 54% had proliferative retinopathy.
response to standing; and heart rate variabili‑
ty time and frequency domain indices. CAN was 
diagnosed when abnormalities were present in 
more than 1 test.10,11
A smoker was defined as a patient smoking 
at  least 1 cigarette, pipe, or cigar daily, or as 
a patient who had stopped smoking in the past 
3 months.
Severe hypoglycemia was defined as an event 
requiring assistance of another person to adminis‑
ter carbohydrates, glucagon, or both. In fact, plas‑
ma glucose concentrations are not always avail‑
able during the event, but the recovery follow‑
ing normalization of plasma glucose is consid‑
ered sufficient evidence that the event had been 
induced by low plasma glucose concentrations.12 
Frequent severe hypoglycemia was defined as 
more than 3 episodes per year. Diabetic retinop‑
athy was diagnosed based on ophthalmologic ex‑
amination with fluorescein angiography at base‑
line and at the end of follow ‑up.
Laboratory assessment Glycated hemoglo‑
bin A1c (HbA1c) levels were assessed using high‑
‑performance liquid chromatography. The final 
results of HbA1c (at the end of follow ‑up) were 
calculated as the median HbA1c concentrations 
during the 7 ‑year follow ‑up.
Albuminuria was diagnosed with a urinary 
albumin ‑to ‑creatinine ratio in a random spot 
urine collection. Increased urinary albumin ex‑
cretion was defined as a creatinine clearance of 
30 mg/g or higher in at least 2 of 3 consecutive 
tests, collected within a 3‑ to 6 ‑month period.
All laboratory measurements were performed 
in the same central laboratory. The results are pre‑
sented in TABLE 1.
Study outcomes The primary study outcome was 
the diagnosis of obstructive or nonobstructive 
CAD. The secondary endpoint was the incidence 
of ACS (such as myocardial infarction or unsta‑
ble angina) and of cardiac death during the 7 ‑year 
follow ‑up. The outcomes were evaluated indepen‑
dently by an adjudication committee consisting 
of experienced cardiologists.
Pharmacological treatment During the study, pa‑
tients were treated using the regimen of multi‑
ple (4 or more) insulin injections or an insulin 
pump (10 patients). All participants were treat‑
ed in agreement with the current cardiac and di‑
abetes guidelines.
Statistical analysis Continuous variables were ex‑
pressed as medians with the first and third quar‑
tiles, and categorical variables, as numbers and 
percentages. The analysis of variance or the Krus‑
kal–Wallis test was applied where appropriate to 
compare continuous variables across the HbA1c 
quartiles. For categorical variables, the χ2 test was 
used. Baseline and follow ‑up data were compared 
using the paired t test or the Mann–Whitney test 
where appropriate for continuous variables and 
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5% of patients with obstructive CAD and 8% 
of those with nonobstructive CAD reported no 
complaints.
Revascularization procedures At baseline, among 
160 patients with obstructive CAD referred for re‑
vascularization, only 38% underwent complete re‑
vascularization, whereas 42% underwent incom‑
plete revascularization and 20% did not undergo 
any procedure (30 patients had lesions unsuitable 
Of the 160 patients with obstructive CAD, 16% 
had 1 ‑vessel disease, 44% had 2 ‑vessel disease, 
and 40% had 3 ‑vessel or multivessel disease.
Clinical symptoms of ischemia Typical angina on 
exertion was noted in 45% of patients with ob‑
structive CAD and in 43% of those with nonob‑
structive CAD, while exercise intolerance was ob‑
served in 50% of patients with obstructive CAD 
and 49% of those with nonobstructive CAD; 
FIGURE 1 Patient flow through the study 
Abbreviations: ACS, acute coronary syndrome; CAD, coronary artery disease; ETT, exercise treadmill test; no -CAD, nonobstructive CAD; o -CAD, 
obstructive CAD; SPECT, single -photon emission computed tomography; T1D, type 1 diabetes; Type 1, normal coronary anatomy (<20% stenosis) in all 
coronary arteries; Type 2, any stenosis of 20% or higher but less than 70%, narrowing in any epicardial artery, or stenosis of 20% or higher but less than 
50% in the left main artery
20 patients lost at baseline
o-CAD
(n = 160)
Type 1
(n = 704)
Follow-up
Baseline
ETT or SPECT
Coronary angiography
o-CAD
(n = 10)
Type 1
(n = 100)
New CAD
(n = 4) 
Cancer death
(n = 2)
o-CAD
(n = 141)
Cardiac deaths
(n = 25)
ACS
(n = 40)
Summary o-CAD
(n = 155)
New o-CAD
(n = 6)
Type 1
(n = 698)
End of follow-up
Type 2
(n = 266)
no-CAD
Type 2
(n = 266)
Nonfatal ACS
(n = 40)
Nonfatal ACS
(n = 5)
New type 2
(n = 6)
Type 1 diabetes patients (n = 2350)
Negative result
(n = 1194)
Negative result
(n = 1084)
Negative result
(n = 1084)
Positive result
(n = 1130)
Positive result
(n = 110)
n = 2330
No-CAD
Coronary angiographyETT or SPECT
no-CAD
(n = 1064)
Negative result
(n = 1200)
TABLE 2 Prevalence and incidence of significant obstructive and nonobstructive coronary artery disease in patients with type 1 diabetes
Variable Measure HbA1c quartiles, % (mmol/mol)
<7.0 (<53) 
(n = 528)
7.00–7.60 (53–60)
(n = 631)
7.61–8.00 (61–64)
(n = 589)
>8.00 (>64)
(n = 582)
Total
(n = 2330)
Nonobstructive CAD 
prevalence (baseline)
n (%) 48 (9.1) 138 (21.9) 350 (59.4) 434 (74.6) 970 (41.6)
Nonobstructive CAD 
incidence
New cases (%) 5 (1.04) 24 (4.9) 33 (13.8) 38 (25.7) 100 (7.4)
Obstructive CAD prevalence 
(baseline)
n (%) 34 (6.4) 62 (10.0) 42 (7.1) 22 (3.8) 160 (6.9)
Obstructive CAD incidence New cases (%) 15 (3.0) 16 (2.8) 5 (0.9) 4 (0.7) 40 (1.9)
Abbreviations: see TABLE 1 and FIGURE 1
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population). Among patients with ACS, 47% 
had previously diagnosed obstructive CAD (5 pa‑
tients, restenosis after revascularization; 35 pa‑
tients, incomplete revascularization performed 
at baseline).
Surprisingly, the incidence of ACS in patients 
with nonobstructive CAD was similar to that in 
patients with obstructive CAD. Participants with 
nonobstructive CAD type 2 represented 47% of 
all ACS cases, whereas those with type 1, only 
6%. At diagnosis of ACS, 39 patients underwent 
successful PCI, and the remaining ones received 
pharmacological treatment. All patients with ACS 
were symptomatic with chest pain, except 2 par‑
ticipants who had unexplained dyspnea before 
ACS diagnosis.
Of the whole study population, 1.15% were lost 
to follow ‑up. Two patients died due to cancer. Of 
the 25 patients with previously diagnosed ob‑
structive CAD, 4 patients treated with PCI at base‑
line died during follow ‑up due to severe hypo‑
glycemia and sudden cardiac arrest, 10 patients 
who underwent incomplete or no revasculariza‑
tion died due to ACS with subsequent cardiogenic 
shock, 9 patients with incomplete revasculariza‑
tion died due to refractory heart failure, and 2 pa‑
tients after successful revascularization at base‑
line died a few years later due to pulmonary em‑
bolism and cardiogenic shock.
DISCUSSION In this study, we attempted to as‑
sess the current prevalence and incidence, as well 
as the predictors and outcomes, of obstructive 
and nonobstructive CAD in a real ‑life cohort of 
2330 patients with long ‑lasting type 1 diabetes. 
Although this study was not designed to investi‑
gate specific interventions, we observed an im‑
provement in glycemic control as well as treat‑
ment of hypertension and dyslipidemia during 
the 7 ‑year follow ‑up. The improvement of gly‑
cemic control was associated with an increase in 
body mass index and the number of hypoglyce‑
mia episodes in some patients, but we also not‑
ed an improvement of the lipid profile. Of note, 
despite low rates of statin use (less than half 
of the population in our study), the incidence 
of obstructive CAD was relatively low. Howev‑
er, the evidence for clinical benefits of statin 
use in patients with type 1 diabetes is limited. 
A meta ‑analysis by the Cholesterol Treatment 
Trialists Collaborators revealed a nonsignifi‑
cant 21% relative risk reduction of major car‑
diovascular events among 1466 patients with 
type 1 diabetes.13
There is also much confusion about symp‑
toms of myocardial ischemia in diabetic pop‑
ulation, and it is widely believed that patients 
with CAD are commonly symptomless. This is 
in contrast to our results because most patients 
with both obstructive and nonobstructive CAD 
were symptomatic, but the most common symp‑
tom was exercise intolerance, while typical an‑
gina was reported in over 40% of patients with 
ischemia. Therefore, it is extremely important 
for any revascularization and 2 patients did not 
give their consent to undergo CABG). PCI with 
drug ‑eluting stent implantation was performed 
in 80% of patients undergoing revascularization 
if technically feasible and safe for the patients. 
Surgical revascularization was performed only 
in 20% of patients, as the remaining ones had 
lesions not suitable for CABG.
In patients with multivessel CAD, left main 
CAD, or when appropriate, the choice of the re‑
vascularization method was at the discretion of 
cardiologists and a cardiac surgeon.
Cardiac events During follow ‑up, ACSs were 
diagnosed in 85 patients (3.6% of the study 
TABLE 3 Predictors of obstructive coronary artery disease in type 1 diabetes
Predictors of obstructive CAD OR 95% CI P value
Univariate analysis
Frequent severe hypoglycemia 1.4 1.2–3.0 0.002
Diabetes duration per year 2.0 1.5–3.5 0.001
eGFR <60 ml/min/1.73 m² 0.8 0.1–2.2 0.003
Hypertension 2.9 2.1–5.0 0.001
HDL -C, mmol/l 0.1 0.5–1.9 0.01
Albuminuria 1.5 1.2–2.9 0.001
Age per year 3.4 1.5–4.1 <0.0001
Multivariate analysis
Age per year 1.9 1.4–2.3 <0.0001
Diabetes duration per year 1.3 1.07–3.2 0.009
Hypertension 2.1 1.4–2.9 <0.0001
eGFR <60 ml/min/1.73 m² 1.6 1.0–3.4 0.02
Abbreviations: OR, odds ratio; others, see TABLE 1 and FIGURE 1
TABLE 4 Predictors of nonobstructive coronary artery disease in type 1 diabetes
Predictors of nonobstructive CAD OR 95% CI P value
Univariate analysis
Age per year 1.1 1.1–2.2 0.01
Diabetes duration per year 1.9 1.0–2.6 <0.0001
HbA1c, % 2.7 2.4–3.1 <0.0001
eGFR <60 ml/min/1.73 m² 1.0 0.9–2.3 0.003
Hypertension 2.8 1.2–5.4 <0.0001
Triglycerides, mmol/l 1.6 1.3–2.0 <0.0001
CAN 1.9 1.2–3.0 <0.0001
LDL -C, mmol/l 1.2 1.0–2.1 0.03
Frequent severe hypoglycemia 1.5 1.0–2.9 0.002
Multivariate analysis
Diabetes duration per year 1.4 1.0–2.3 0.001
HbA1c, % 2.0 1.8–2.9 <0.0001
Frequent severe hypoglycemia 1.3 1.0–2.0 0.001
Hypertension 1.9 1.3–2.3 <0.00001
Triglycerides, mmol/l 1.2 1.0–2.0 0.02
eGFR <60 ml/min/1.73 m² 1.5 1.1–2.9 0.0003
CAN 1.1 1.0–2.1 0.01
Abbreviations: CAN, cardiac autonomic neuropathy; others, see TABLE 1, TABLE 3, and 
FIGURE 1
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similar to that in patients with obstructive CAD, 
whereas in patients with nonobstructive CAD 
type 1, the incidence was definitely lower than 
in participants with obstructive CAD.
The incidence of ACS and cardiac deaths in 
the whole study population was relatively low. 
This is in line with the results of Rawshani et al,19 
who reported an incidence of ACS of 2.4% and 
a reduction of fatal outcomes among patients with 
type 1 diabetes, with no differences in compari‑
son with nondiabetic controls.20 However, other 
studies reported a cumulative mortality for CAD 
of 6% to 8%.1,8,21
In patients with obstructive CAD who under‑
go incomplete or no revascularization, the prog‑
nosis is still poor.21 In our study, 15.6% of pa‑
tients with obstructive CAD died during follow‑
‑up because of coronary lesions unsuitable for 
revascularization.
In the present study, diabetes duration, hy‑
pertension, and kidney failure were independent 
predictors of both obstructive and nonobstruc‑
tive CAD, while frequent severe hypoglycemia, 
HbA1c levels, and elevated serum triglyceride lev‑
els predicted the prevalence of nonobstructive 
CAD. The effect of diabetes duration, hyperten‑
sion, kidney failure, and lipid disorders on the in‑
cidence of vascular complications in this popu‑
lation is well established in clinical studies.1,22,23
The effects of hyperglycemia, hypoglycemia, 
and glycemic variability on the development of 
cardiovascular complications have been widely 
discussed; however, their influence on the rate 
of nonobstructive CAD has not been evaluated 
in clinical studies.24-26 In our study, hyperglyce‑
mia increased the risk of nonobstructive CAD 
but had no effect on the prevalence of obstruc‑
tive CAD. The results of Diabetes Control and 
Complications Trial / Epidemiology of Diabetes 
Interventions and Complications also confirmed 
the relationship between chronic hyperglycemia 
and microvascular, but not macrovascular, com‑
plications.27 Similarly to our findings, hypergly‑
cemia was not a predictor of CAD in a 10 ‑year 
follow ‑up report from the Pittsburgh Epidemi‑
ology of Diabetes Complications and Eurodiab 
studies,1,17 while the importance of tight glyce‑
mic control for protection against CAD has been 
reported in other papers.1,28
Our study revealed that nonobstructive CAD 
with ischemia symptoms as a microvascular dis‑
ease is the most common coronary complication 
in patients with type 1 diabetes. On the other 
hand, macrovascular complications are more com‑
mon in type 2 than in type 1 diabetes.5,6,29-33 Fur‑
thermore, macrovascular complications in pa‑
tients with type 2 diabetes are often recognized 
earlier than diabetes itself.33,34
Obstructive and nonobstructive CAD differs 
in prevalence but has similar nonfatal outcomes 
and shares the same predictors including diabe‑
tes duration, hypertension, and renal failure. Pos‑
itive results of ETT/SPECT with concomitant clin‑
ical symptoms of ischemia are related to glycemic 
to distinguish exercise intolerance as a separate 
symptom of ischemia in diabetic patients after 
exclusion of other causes.
Despite long diabetes duration, the prevalence 
of obstructive CAD was consistent with angiog‑
raphy or autopsy findings from previous studies 
in the general nondiabetic population at a sim‑
ilar age.14,15 Moreover, in our study, we did not 
confirm a higher prevalence of premature ob‑
structive CAD in comparison with data reported 
for the general population in earlier studies.1 We 
also revealed a low incidence of obstructive CAD. 
In contrast, the cumulative incidence of obstruc‑
tive CAD in previously published studies ranged 
from 2.1% to 19%, with most of them reporting 
a cumulative incidence of approximately 15 years 
of follow ‑up.8,16,17
Some studies indicated that diabetes appears to 
attenuate the protective effect of the female sex 
on the development of cardiovascular complica‑
tions.18 This is in contrast to our results because 
in our population, obstructive CAD was less com‑
mon in women, and women were also older than 
men at diagnosis of obstructive CAD.
Although in the present study the prevalence 
of obstructive CAD was low, we found that ETT 
and 99mTc ‑sestamibi SPECT, which are recom‑
mended as the first ‑line noninvasive diagnos‑
tic procedures in cardiological guidelines, have 
a limited diagnostic value related to their sen‑
sitivity and specificity in detecting myocardial 
ischemia. Therefore, it is possible that the per‑
centage of obstructive CAD cases was slightly 
underestimated. This constitutes the first limi‑
tation of our study. On the other hand, during 
the 7 ‑year follow ‑up, most patients with undiag‑
nosed obstructive CAD would have ACS or oth‑
er signs of ischemia. However, we were in con‑
tact with the patients and their doctors during 
follow ‑up, and we also assessed participants 
at the end of follow ‑up, so any events were un‑
likely to have been missed.
In our study, patients with nonobstructive 
CAD and ischemia represented a larger and more 
heterogeneous group than those with obstruc‑
tive CAD. The nonobstructive group encom‑
passed patients with normal epicardial arteries 
and those with nonsignificant lesions on angi‑
ography. In patients with nonobstructive CAD, 
the presence of persistent chest pain or signifi‑
cant exercise intolerance, along with coexisting 
ischemia on ETT/SPECT, allowed us to estab‑
lish the diagnosis of microvascular disease. On 
the other hand, due to inherent limitations of 
ETT/SPECT and all current methods for the di‑
agnosis of microvascular disease, the number 
of cases was certainly underestimated. Further‑
more, we realize that microvascular disease may 
occur in some patients together with obstruc‑
tive CAD, so the prevalence of microvascular dis‑
ease may also have been underestimated. This 
constitutes another limitation of our study. On 
the other hand, the incidence of nonfatal ACS 
in patients with nonobstructive CAD type 2 was 
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control, CAN, frequent severe hypoglycemia, tri‑
glyceride levels in patients with diabetes and non‑
obstructive CAD, but not in those with obstruc‑
tive CAD. In the era of modern therapy of diabe‑
tes and concomitant disorders, the prevalence, in‑
cidence, predictors, and outcomes of obstructive 
and nonobstructive CAD should be continuously 
evaluated to identify patients requiring person‑
alized and intensified treatment.
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